BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial

BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial

Background: For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity, better adherence and cost savings. Objectives: To determine whether or n...

Full description

Bibliographic Details
Main Authors: Karina Butler, Jamie Inshaw, Deborah Ford, Sarah Bernays, Karen Scott, Julia Kenny, Nigel Klein, Anna Turkova, Lynda Harper, Eleni Nastouli, Sara Paparini, Rahela Choudhury, Tim Rhodes, Abdel Babiker, Diana Gibb, on behalf of the PENTA team
Format: Article
Language:English
Published: NIHR Journals Library 2016-06-01
Series:Health Technology Assessment
Subjects:
randomised trial
human immunodeficiency virus
short-cycle therapy
continuous therapy
antiretroviral therapy
efavirenz
Online Access:https://doi.org/10.3310/hta20490

Internet

https://doi.org/10.3310/hta20490

Similar Items